PubRank

Julie Vose

Author PubWeight™ 65.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002 24.07
2 Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004 12.20
3 The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003 6.11
4 Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003 6.06
5 Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2008 3.56
6 Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014 1.66
7 Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007 1.60
8 Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2002 1.57
9 Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 2009 1.07
10 The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2010 1.06
11 Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010 1.05
12 The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 2011 1.00
13 Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol 2011 0.99
14 Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist 2009 0.95
15 Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 2009 0.91
16 Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs 2002 0.85
17 Radioimmunotherapy: a novel treatment modality for B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2003 0.82
18 High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011 0.80
19 The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component. Br J Haematol 2008 0.76
20 Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma? Clin Lymphoma Myeloma Leuk 2013 0.76
21 Early-stage Hodgkin disease in a 24-year-old woman. Semin Oncol 2011 0.75
22 The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2003 0.75
23 Non-Hodgkin lymphoma of the prostate. Am J Hematol 2011 0.75